These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
453 related articles for article (PubMed ID: 26853139)
21. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke. Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996 [TBL] [Abstract][Full Text] [Related]
22. Thrombolytic therapy with intravenous recombinant tissue plasminogen activator in Japanese older patients with acute ischemic stroke: Fukuoka Stroke Registry. Matsuo R; Kamouchi M; Ago T; Hata J; Shono Y; Kuroda J; Wakisaka Y; Sugimori H; Kitazono T; Geriatr Gerontol Int; 2014 Oct; 14(4):954-9. PubMed ID: 24320947 [TBL] [Abstract][Full Text] [Related]
23. Lipid-Lowering Pretreatment and Outcome Following Intravenous Thrombolysis for Acute Ischaemic Stroke: A Post Hoc Analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study Trial. Minhas JS; Wang X; Arima H; Bath PM; Billot L; Broderick JP; Donnan GA; Kim JS; Lavados PM; Lee TH; Martins SCO; Olavarría VV; Pandian JD; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Thang NH; Wang JG; Woodward M; Chalmers J; Anderson CS; Robinson TG; Cerebrovasc Dis; 2018; 45(5-6):213-220. PubMed ID: 29705803 [TBL] [Abstract][Full Text] [Related]
25. Intravenous Thrombolysis and Passes of Thrombectomy as Predictors for Endovascular Revascularization in Ischemic Stroke. Angermaier A; Michel P; Khaw AV; Kirsch M; Kessler C; Langner S J Stroke Cerebrovasc Dis; 2016 Oct; 25(10):2488-95. PubMed ID: 27495833 [TBL] [Abstract][Full Text] [Related]
26. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke. Wolfe T; Suarez JI; Tarr RW; Welter E; Landis D; Sunshine JL; Zaidat OO J Stroke Cerebrovasc Dis; 2008; 17(3):121-8. PubMed ID: 18436152 [TBL] [Abstract][Full Text] [Related]
27. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator. Ong CT; Wong YS; Wu CS; Su YH Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721 [TBL] [Abstract][Full Text] [Related]
28. Renal Dysfunction Associated with Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis. Zhu J; Shen X; Han C; Mei C; Zhou Y; Wang H; Kong Y; Jiang Y; Fang Q; Cai X J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104363. PubMed ID: 31501038 [TBL] [Abstract][Full Text] [Related]
29. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator. Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898 [TBL] [Abstract][Full Text] [Related]
30. Very Early versus Delayed Rehabilitation for Acute Ischemic Stroke Patients with Intravenous Recombinant Tissue Plasminogen Activator: A Nationwide Retrospective Cohort Study. Momosaki R; Yasunaga H; Kakuda W; Matsui H; Fushimi K; Abo M Cerebrovasc Dis; 2016; 42(1-2):41-8. PubMed ID: 26986718 [TBL] [Abstract][Full Text] [Related]
31. Aphasia predicts unfavorable outcome in mild ischemic stroke patients and prompts thrombolytic treatment. Nesi M; Lucente G; Nencini P; Fancellu L; Inzitari D J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):204-8. PubMed ID: 23352114 [TBL] [Abstract][Full Text] [Related]
32. Intravenous Thrombolysis for Stroke Patients with G6PD Deficiency. Wu X; Fu R; Tang Y; Shi L; Rong X; Guo J; Li J; Shen Q J Stroke Cerebrovasc Dis; 2018 Jul; 27(7):2026-2031. PubMed ID: 29653805 [TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy of Intravenous Thrombolytic Therapy in Patients With Acute Posterior Circulation Stroke: A Single-Center Study. Zhu X; Wang N; Lin H; Zhang P; Chen L; Zhang M; Deng B; Wu T J Stroke Cerebrovasc Dis; 2020 Feb; 29(2):104537. PubMed ID: 31806454 [TBL] [Abstract][Full Text] [Related]
34. The iScore predicts clinical response to tissue plasminogen activator in Korean stroke patients. Park TH; Park SS; Ko Y; Lee SJ; Lee KB; Lee J; Kang K; Park JM; Choi JC; Kim DE; Cho YJ; Hong KS; Kim JT; Kim DH; Cha JK; Han MK; Lee JS; Lee J; Yu KH; Lee BC; Yoon BW; Bae HJ; Saposnik G J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):367-73. PubMed ID: 23800501 [TBL] [Abstract][Full Text] [Related]
36. Correlation of Changes in Leukocytes Levels 24 Hours after Intravenous Thrombolysis With Prognosis in Patients With Acute Ischemic Stroke. Chen J; Zhang Z; Chen L; Feng X; Hu W; Ge W; Li X; Jin P; Shao B J Stroke Cerebrovasc Dis; 2018 Oct; 27(10):2857-2862. PubMed ID: 30064868 [TBL] [Abstract][Full Text] [Related]
38. Preclusion of ischemic stroke patients from intravenous tissue plasminogen activator treatment for mild symptoms should not be based on low National Institutes of Health Stroke Scale Scores. Wendt M; Tütüncü S; Fiebach JB; Scheitz JF; Audebert HJ; Nolte CH J Stroke Cerebrovasc Dis; 2013 May; 22(4):550-3. PubMed ID: 23433783 [TBL] [Abstract][Full Text] [Related]
39. Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator. Betts KA; Hurley D; Song J; Sajeev G; Guo J; Du EX; Paschoalin M; Wu EQ J Stroke Cerebrovasc Dis; 2017 Sep; 26(9):1996-2003. PubMed ID: 28689999 [TBL] [Abstract][Full Text] [Related]
40. Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan. Fang CW; Tsai YT; Chou PC; Chen HM; Lu CM; Tsao CR; Chen CL; Sun MC; Shih YS; Hsieh CY; Chen LA; Chen PL; Yeh JT; Li YH J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):815-820. PubMed ID: 30573284 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]